Fennec to Present at the Cantor Fitzgerald Global Healthcare Conference on September 27, 2017 in New York City
September 20 2017 - 7:30AM
Fennec Pharmaceuticals, Inc. (NASDAQ:FENC) (TSX:FRX), today
announced that Rosty Raykov, CEO of Fennec, will be presenting at
the Cantor Fitzgerald Global Healthcare Conference in New York on
September 27 at 4:00 pm. Management will also be available to meet
with investors during the conference.
The Fennec presentation will be webcast live and
can be accessed by visiting the investor relations section of the
Company's website at
http://fennecpharma.com/investors/presentations-events/. A
replay of the presentation will also be available and archived on
the site for ninety days.
About Fennec
Pharmaceuticals
Fennec Pharmaceuticals, Inc., is a specialty
pharmaceutical company focused on the development of PEDMARKTM (a
unique formulation of sodium thiosulfate). PEDMARKTM has received
Orphan Drug Designation in the US in this setting. For more
information, please visit www.fennecpharma.com.
Forward looking statements
Except for historical information described in
this press release, all other statements are forward-looking.
Forward-looking statements are subject to certain risks and
uncertainties inherent in the Company’s business that could cause
actual results to vary, including such risks that regulatory and
guideline developments may change, scientific data may not be
sufficient to meet regulatory standards or receipt of required
regulatory clearances or approvals, clinical results may not be
replicated in actual patient settings, protection offered by the
Company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the Company’s products will not be as large as expected,
the Company’s products will not be able to penetrate one or more
targeted markets, revenues will not be sufficient to fund further
development and clinical studies, the Company may not meet its
future capital requirements in different countries and
municipalities, and other risks detailed from time to time in the
Company’s filings with the Securities and Exchange Commission
including its Annual Report on Form 10-K for the year ended
December 31, 2016. Fennec Pharmaceuticals, Inc. disclaims any
obligation to update these forward-looking statements except as
required by law.
For a more detailed discussion of related risk
factors, please refer to our public filings available at
www.sec.gov and www.sedar.com.
For further information, please contact:Rosty
RaykovChief Executive OfficerFennec Pharmaceuticals Inc.T: (919)
636-5144
Fennec Pharmaceuticals (TSX:FRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fennec Pharmaceuticals (TSX:FRX)
Historical Stock Chart
From Apr 2023 to Apr 2024